Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Creo Medical ( (GB:CREO) ) just unveiled an announcement.
Creo Medical Group plc has announced a change in its Nominated Adviser and Broker from Numis Securities Limited to Deutsche Bank AG, London Branch. This change follows the acquisition of Numis Securities’ parent company by Deutsche Bank AG. The shift is expected to impact Creo Medical’s operations by aligning with a globally recognized financial institution, potentially enhancing its market positioning and stakeholder confidence.
Spark’s Take on GB:CREO Stock
According to Spark, TipRanks’ AI Analyst, GB:CREO is a Neutral.
Creo Medical’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. However, positive corporate events and neutral technical indicators provide some offset, suggesting potential for future improvement if financial challenges are addressed.
To see Spark’s full report on GB:CREO stock, click here.
More about Creo Medical
Creo Medical Group plc is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices. The company focuses on enhancing surgical endoscopy for pre-cancer and cancer patients by providing advanced energy solutions through its CROMA technology, powered by Kamaptive. This technology integrates multi-modal energy sources to improve surgical precision and patient outcomes, offering a safer and more cost-efficient alternative for surgical procedures.
Average Trading Volume: 1,893,630
Technical Sentiment Signal: Sell
Current Market Cap: £55.17M
Learn more about CREO stock on TipRanks’ Stock Analysis page.